PL3558391T3 - Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania - Google Patents
Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowaniaInfo
- Publication number
- PL3558391T3 PL3558391T3 PL17835533T PL17835533T PL3558391T3 PL 3558391 T3 PL3558391 T3 PL 3558391T3 PL 17835533 T PL17835533 T PL 17835533T PL 17835533 T PL17835533 T PL 17835533T PL 3558391 T3 PL3558391 T3 PL 3558391T3
- Authority
- PL
- Poland
- Prior art keywords
- adam9
- methods
- immunoconjugates targeting
- immunoconjugates
- targeting
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438488P | 2016-12-23 | 2016-12-23 | |
US201762480201P | 2017-03-31 | 2017-03-31 | |
EP17835533.5A EP3558391B1 (fr) | 2016-12-23 | 2017-12-21 | Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation |
PCT/US2017/067823 WO2018119196A1 (fr) | 2016-12-23 | 2017-12-21 | Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3558391T3 true PL3558391T3 (pl) | 2022-05-16 |
Family
ID=61025051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17835533T PL3558391T3 (pl) | 2016-12-23 | 2017-12-21 | Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210388102A1 (fr) |
EP (1) | EP3558391B1 (fr) |
JP (1) | JP7170642B2 (fr) |
CN (1) | CN110267685B (fr) |
DK (1) | DK3558391T3 (fr) |
ES (1) | ES2912266T3 (fr) |
HR (1) | HRP20220550T1 (fr) |
HU (1) | HUE058664T2 (fr) |
LT (1) | LT3558391T (fr) |
MD (1) | MD3558391T2 (fr) |
PL (1) | PL3558391T3 (fr) |
PT (1) | PT3558391T (fr) |
RS (1) | RS63154B1 (fr) |
SI (1) | SI3558391T1 (fr) |
TW (1) | TWI783957B (fr) |
WO (1) | WO2018119196A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51629A (fr) | 2018-01-12 | 2020-11-18 | Immunogen Inc | Procédés de production, purification et formulation de conjugués anticorps-médicaments |
CA3104511A1 (fr) * | 2018-06-26 | 2020-01-02 | Immunogen, Inc. | Immunoconjugues ciblant l'adam9 et methodes d'utilisation associes |
AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
CN113661172A (zh) | 2019-03-29 | 2021-11-16 | 伊缪诺金公司 | 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物 |
CA3137125A1 (fr) | 2019-04-26 | 2020-10-29 | Immunogen, Inc. | Derives de camptothecine |
CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
CN117729942A (zh) | 2021-03-08 | 2024-03-19 | 伊缪诺金公司 | 用于增加靶向adam9的免疫缀合物治疗癌症的功效的方法 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
CA2078539C (fr) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Procede de fabrication de chimere d'anticorps humain |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
EP1142910A1 (fr) | 2000-04-07 | 2001-10-10 | Jürgen Prof. Dr. Frey | Des inhibiteurs de la formation du facteur soluble humain CD23 |
US20030091568A1 (en) | 2000-04-07 | 2003-05-15 | Jurgen Frey | Inhibitors for the formation of soluble human CD23 |
EP1355919B1 (fr) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules a demi-vies longues, compositions et utilisations de celles-ci |
AU2002347182A1 (en) | 2001-12-18 | 2003-06-30 | Mondobiotech Licensing Out Ag | Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US20040092466A1 (en) | 2002-11-11 | 2004-05-13 | Isis Pharmaceuticals Inc. | Modulation of ADAM9 expression |
AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
DE10337368A1 (de) * | 2003-08-08 | 2005-03-03 | Technische Universität Dresden | Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren |
JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
WO2005091823A2 (fr) | 2004-03-01 | 2005-10-06 | The Regents Of The University Of California | Utilisation du peptide lunasine comme activateur transcriptionnel dans la prevention du cancer et methodes de traitement apparentees, surveillance continue et pronostic |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
NZ556561A (en) | 2005-02-02 | 2011-08-26 | Macrogenics West Inc | Adam-9 modulators |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
TWI523864B (zh) | 2006-05-30 | 2016-03-01 | 建南德克公司 | 抗體及免疫接合物及其用途 |
WO2007143752A2 (fr) | 2006-06-09 | 2007-12-13 | The Regents Of The University Of California | Cibles pour le pronostic ou la thérapie dans le cancer du sein |
KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
PT2019104E (pt) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
GB2453589A (en) | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
US8101361B2 (en) | 2008-03-10 | 2012-01-24 | National Jewish Health | Markers for diagnosis of pulmonary inflammation and methods related thereto |
AU2009233899A1 (en) | 2008-04-07 | 2009-10-15 | Zymogenetics, Inc. | Thrombin activator compostions and methods of making and using the same |
US20090285840A1 (en) * | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
KR101764081B1 (ko) | 2008-04-30 | 2017-08-01 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
ES2675730T3 (es) | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos |
WO2010014990A2 (fr) | 2008-08-01 | 2010-02-04 | The Board Of Trustees Of The University Of Illinois | Méthode de promotion de neurogenèse par modulation des activités secrétases |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
US20100112713A1 (en) | 2008-11-05 | 2010-05-06 | The Texas A&M University System | Methods For Detecting Colorectal Diseases And Disorders |
SG171812A1 (en) | 2008-12-04 | 2011-07-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
MX2011008328A (es) | 2009-02-05 | 2011-11-04 | Immunogen Inc | Derivados novedosos de benzodiacepina. |
TR201907573T4 (tr) | 2009-06-03 | 2019-06-21 | Immunogen Inc | Konjugasyon yöntemleri̇ |
EP2534171A4 (fr) | 2010-02-11 | 2013-07-17 | Univ Southern California | Polypeptides modifiés du domaine désintégrine adam, et leurs utilisations |
CN106279416B (zh) | 2010-03-04 | 2019-08-30 | 宏观基因有限公司 | 与b7-h3反应性的抗体、其免疫学活性片段及其用途 |
EP2789622B1 (fr) | 2010-04-15 | 2017-03-01 | MedImmune Limited | Pyrrolobenzodiazepines utilisés pour traiter des maladies proliférantes |
DK2675479T3 (en) | 2011-02-15 | 2016-04-11 | Immunogen Inc | cytotoxic benzodiazepine |
UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US20130130355A1 (en) | 2011-09-28 | 2013-05-23 | Armune Biosciences, Inc. | Method and system of particle-phage epitope complex |
US20140342946A1 (en) | 2011-12-31 | 2014-11-20 | Moni Abraham Kuriakose | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
WO2013177481A1 (fr) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazépines et leurs conjugués |
WO2014108480A1 (fr) | 2013-01-09 | 2014-07-17 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Procédé pour la détection in vitro et la surveillance d'une maladie par la mesure de l'activité protéase associée à une maladie dans des vésicules extracellulaires |
CA2900764A1 (fr) | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Nouvelles constructions multispecifiques |
EP2985346A4 (fr) | 2013-04-08 | 2016-05-25 | Mitsubishi Rayon Co | Microréseau pour évaluer une maladie oculaire et procédé d'évaluation d'une maladie oculaire |
CA2912542A1 (fr) | 2013-05-13 | 2014-11-20 | Tufts University | Methodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8 |
CA2915823A1 (fr) | 2013-06-19 | 2014-12-24 | Memorial Sloan-Kettering Cancer Center | Methodes et compositions pour le diagnostic, le pronostic et le traitement de metastases cerebrales |
US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
CA2957964A1 (fr) * | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Conjugues comprenant des agents de liaison cellulaire et des agents cytotoxiques |
SG11201701455SA (en) | 2014-09-03 | 2017-03-30 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
WO2016036804A1 (fr) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxique |
US20180125988A1 (en) | 2014-11-11 | 2018-05-10 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
AU2016285929B2 (en) | 2015-06-29 | 2022-01-06 | Immunogen, Inc. | Conjugates of cysteine engineered antibodies |
-
2017
- 2017-12-21 JP JP2019533514A patent/JP7170642B2/ja active Active
- 2017-12-21 SI SI201731135T patent/SI3558391T1/sl unknown
- 2017-12-21 WO PCT/US2017/067823 patent/WO2018119196A1/fr unknown
- 2017-12-21 TW TW106145085A patent/TWI783957B/zh active
- 2017-12-21 EP EP17835533.5A patent/EP3558391B1/fr active Active
- 2017-12-21 HU HUE17835533A patent/HUE058664T2/hu unknown
- 2017-12-21 HR HRP20220550TT patent/HRP20220550T1/hr unknown
- 2017-12-21 DK DK17835533.5T patent/DK3558391T3/da active
- 2017-12-21 CN CN201780079982.XA patent/CN110267685B/zh active Active
- 2017-12-21 PT PT178355335T patent/PT3558391T/pt unknown
- 2017-12-21 LT LTEPPCT/US2017/067823T patent/LT3558391T/lt unknown
- 2017-12-21 RS RS20220395A patent/RS63154B1/sr unknown
- 2017-12-21 MD MDE20191243T patent/MD3558391T2/ro unknown
- 2017-12-21 PL PL17835533T patent/PL3558391T3/pl unknown
- 2017-12-21 ES ES17835533T patent/ES2912266T3/es active Active
- 2017-12-21 US US16/469,494 patent/US20210388102A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI783957B (zh) | 2022-11-21 |
JP7170642B2 (ja) | 2022-11-14 |
CN110267685B (zh) | 2023-06-20 |
SI3558391T1 (sl) | 2022-06-30 |
ES2912266T3 (es) | 2022-05-25 |
PT3558391T (pt) | 2022-05-05 |
WO2018119196A1 (fr) | 2018-06-28 |
JP2020504607A (ja) | 2020-02-13 |
CN110267685A (zh) | 2019-09-20 |
HUE058664T2 (hu) | 2022-09-28 |
DK3558391T3 (da) | 2022-05-09 |
LT3558391T (lt) | 2022-07-11 |
EP3558391B1 (fr) | 2022-02-02 |
EP3558391A1 (fr) | 2019-10-30 |
RS63154B1 (sr) | 2022-05-31 |
US20210388102A1 (en) | 2021-12-16 |
TW201822821A (zh) | 2018-07-01 |
MD3558391T2 (ro) | 2022-05-31 |
HRP20220550T1 (hr) | 2022-06-10 |
WO2018119196A8 (fr) | 2019-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290809B1 (en) | Tau-protein targeted protacs and related methods of use | |
IL261428A (en) | Antibody-drug conjugates based on eribulin and methods of use | |
IL261493A (en) | Napi2b-targeted antibody conjugates - drug and methods of using them | |
IL265156A (en) | Immunogenic preparations that target recurrent cancer mutations and methods for their use | |
IL254811A0 (en) | Hahaha | |
HK1217086A1 (zh) | 護理角蛋白的製劑及方法 | |
GB2539350B (en) | Amyloid targeting agents and methods of using the same | |
SI3558391T1 (sl) | Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe | |
IL261996A (en) | A new RNA structure and methods for using it to improve the therapeutic effects of cytotoxic cells and stem cells | |
EP3177638A4 (fr) | Peptides de ciblage et méthodes d'utilisation | |
IL265870A (en) | Nanoparticle formulations and methods of making and using thereof | |
IL265881A (en) | Inhaler and methods of use thereof | |
IL285928A (en) | Fulvestrant formulations and methods of using them | |
IL265955A (en) | Therapeutic compounds and methods of use thereof | |
RS65120B1 (sr) | Farmaceutske formulacije i postupci za njihovu upotrebu | |
IL249894A0 (en) | Targeted medical nanoparticles and methods for their preparation and use | |
HK1258409A1 (zh) | 抗cd22抗體-美登木素綴合物及其使用方法 | |
IL279633A (en) | Immunoconjugates targeting ADAM9 and methods of using them | |
HK1256368A1 (zh) | 加利車黴素-抗體-藥物綴合物和使用方法 | |
IL274433A (en) | Fulvestrant formulations and methods of using them | |
ZA201908264B (en) | Formulations of homotaurines and salts thereof | |
IL234161A0 (en) | Device and methods of use that combine magnetotherapy and aromatherapy |